Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 280

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 280
---
 Notes and 2021 Notes:

| Balance as of December 31, 2021                        |     | $ |  6,075 |   |
| Changes in fair value                                  |     |   |    397 |   |
| Balance as of December 31, 2022                        |     | $ |  6,472 |   |
| Balance as of December 31, 2022                        |     | $ |  6,472 |   |
| Conversion of the 2021 Notes into preferred D-2 shares |     |   | (1,086 | ) |
| Changes in fair value                                  |     |   |  2,019 |   |
| Balance as of December 31, 2023                        |     | $ |  7,405 |   |

<div align='center'>F-32</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | WARRANT LIABILITY |

| a. | During 2015, the Company issued 66,946 warrants in connection with the issuance of its convertible notes which are exercisable into convertible preferred D-2 shares. The warrants are exercisable at the earlier of: (i) until March 1, 2025 or (ii) immediately prior to the closing of an IPO or Deemed Liquidation Event, or immediately prior to the occurrence of a Liquidation Event, as described in Company’s Article of Association (the “AOA”). |

A Deemed Liquidation Event, as defined
in Company’s AOA, includes change of control event in which shareholders of the Company, immediately prior to the event, hold less
than 50% of the voting power in the Company (or the surviving entity) after the event, as well as an event in which the Company sells
substantially all of its assets. In the occurrence of a Deemed Liquidation Event, all of the Company’s assets legally available
for distribution among the shareholders of the Company would be distributed in accordance with the preference described
above. A Liquidation Event, as defined in Company’s AOA, includes any dissolution, winding-up or liquidation of the Company, and
any foreclosure by creditors of the Company on substantially all assets of, or equity interests in the Company, all whether voluntarily
or involuntarily.

The exercise price of each warrant is
$38.01